Gilead Sciences (FRA:GIS) LT-Debt-to-Total-Asset: 0.37 (As of Mar. 2026)

What is Gilead Sciences LT-Debt-to-Total-Asset?

Gilead Sciences FRA:GIS +4.15% 69 LT-Debt-to-Total-Asset is 0.37 as of Mar. 2026. GuruFocus rates FRA:GIS with a GF Score™ of 69/100 and a GF Value™ of €82.35 (Significantly Overvalued). The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Gilead Sciences's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.37.

Gilead Sciences's long-term debt to total assets ratio declined from Mar. 2025 (0.39) to Mar. 2026 (0.37). It may suggest that Gilead Sciences is progressively becoming less dependent on debt to grow their business.

Gilead Sciences (FRA:GIS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Gilead Sciences LT-Debt-to-Total-Asset Related Terms

Gilead Sciences LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Gilead Sciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences LT-Debt-to-Total-Asset Chart

Gilead Sciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.37

0.36

0.37

0.42

0.38

Gilead Sciences Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.39	0.40	0.38	0.38	0.37

69GF Score

Gilead Sciences Inc FRA:GIS

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Gilead Sciences LT-Debt-to-Total-Asset Calculation

Gilead Sciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	18898.166	/	50405.642
	=	0.37

Gilead Sciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	18044.765	/	48680.47
	=	0.37

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.37 mean?

Gilead Sciences (FRA:GIS) has a LT-Debt-to-Total-Asset of 0.37 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Gilead Sciences and its competitors.

Is Gilead Sciences' LT-Debt-to-Total-Asset too high?

Gilead Sciences' current LT-Debt-to-Total-Asset is 0.37. Overall, Gilead Sciences has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Gilead Sciences' LT-Debt-to-Total-Asset compare to PFE and AMGN?

Gilead Sciences' LT-Debt-to-Total-Asset of 0.37 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Gilead Sciences and its competitors. Gilead Sciences's current LT-Debt-to-Total-Asset is 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Gilead Sciences stock overvalued right now?

Based on GuruFocus' analysis, Gilead Sciences (FRA:GIS) is currently considered Significantly Overvalued. The stock's GF Value™ is €82.35, compared to a current price of €117.50 — trading 42.7% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.37. Gilead Sciences' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Gilead Sciences (FRA:GIS), the current LT-Debt-to-Total-Asset is 0.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gilead Sciences (FRA:GIS) Overvalued in 2026?

Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued. The current stock price of €117.50 is trading 42.7% above its estimated GF Value™ of €82.35. GuruFocus considers Gilead Sciences to be Significantly Overvalued.

Key valuation signals for FRA:GIS:

LT-Debt-to-Total-Asset: 0.37
GF Value™: €82.35 vs. price of €117.50 (42.7% above fair value)
GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gilead Sciences Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies PFE AMGN BMY BIIB OGN AMRN SCLX MIRA NSRX MDCX LLY JNJ ABBV XSWX:ROP MRK XSWX:NOVN LSE:AZN OCSE:NOVO B LSE:GSK XPAR:SAN

Other Exchanges GILD:USA GILD:Peru GILD:Mexico 1GILD:Italy 0QYQ:UK GIS:Germany GILD:Canada GILD34:Brazil GILD:Austria GILD:Argentina

Address 333 Lakeside Drive, Foster City, CA, USA, 94404

Website https://www.gilead.com

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

69GF Score

Get the complete analysis for FRA:GIS

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€117.50

Price

€82.35

GF Value

View FRA:GIS Analysis

See LT-Debt-to-Total-Asset data for all stocks →